Evaluation of the Clinical Use of Ceftriaxone among In-Patients in Selected Health Facilities in Uganda
Paul Kutyabami,
Edson Ireeta Munanura,
Rajab Kalidi,
Sulah Balikuna,
Margaret Ndagire,
Bruhan Kaggwa,
Winnie Nambatya,
Pakoyo Fadhiru Kamba,
Allan Musiimenta,
Diana Nakitto Kesi,
Victoria Nambasa,
Allan Serwanga,
Helen Byomire Ndagije
Affiliations
Paul Kutyabami
Department of Pharmacy, School of Health Sciences, College of Health Sciences, Makerere University, University Rd, 10218 Kampala, Uganda
Edson Ireeta Munanura
Department of Pharmacy, School of Health Sciences, College of Health Sciences, Makerere University, University Rd, 10218 Kampala, Uganda
Rajab Kalidi
Department of Pharmacy, School of Health Sciences, College of Health Sciences, Makerere University, University Rd, 10218 Kampala, Uganda
Sulah Balikuna
Department of Pharmacy, School of Health Sciences, College of Health Sciences, Makerere University, University Rd, 10218 Kampala, Uganda
Margaret Ndagire
Department of Pharmacy, School of Health Sciences, College of Health Sciences, Makerere University, University Rd, 10218 Kampala, Uganda
Bruhan Kaggwa
Department of Pharmacy, School of Health Sciences, College of Health Sciences, Makerere University, University Rd, 10218 Kampala, Uganda
Winnie Nambatya
Department of Pharmacy, School of Health Sciences, College of Health Sciences, Makerere University, University Rd, 10218 Kampala, Uganda
Pakoyo Fadhiru Kamba
Department of Pharmacy, School of Health Sciences, College of Health Sciences, Makerere University, University Rd, 10218 Kampala, Uganda
Allan Musiimenta
Department of Statistical Methods and Actuarial Sciences, School of Statistics and Planning, College of Business and Management Sciences, Makerere University, University Rd, 10218 Kampala, Uganda
Diana Nakitto Kesi
Directorate of Product Safety, National Drug Authority, Lumumba Avenue, 10106 Kampala, Uganda
Victoria Nambasa
Directorate of Product Safety, National Drug Authority, Lumumba Avenue, 10106 Kampala, Uganda
Allan Serwanga
Directorate of Product Safety, National Drug Authority, Lumumba Avenue, 10106 Kampala, Uganda
Helen Byomire Ndagije
Directorate of Product Safety, National Drug Authority, Lumumba Avenue, 10106 Kampala, Uganda
Ceftriaxone has a high propensity for misuse because of its high rate of utilization. In this study, we aimed at assessing the appropriateness of the clinical utilization of ceftriaxone in nine health facilities in Uganda. Using the World Health Organization (WHO) Drug Use Evaluation indicators, we reviewed a systematic sample of 885 patients’ treatment records selected over a three (3)-month period. Our results showed that prescriptions were written mostly by medical officers at 53.3% (470/882). Ceftriaxone was prescribed mainly for surgical prophylaxis at 25.3% (154/609), respiratory tract infections at 17% (104/609), and sepsis at 11% (67/609), as well as for non-recommended indications such as malaria at 7% (43/609) and anemia at 8% (49/609). Ceftriaxone was mostly prescribed once daily (92.3%; 817/885), as a 2 g dose (50.1%; 443/885), and for 5 days (41%; 363/885). The average score of inappropriate use of ceftriaxone in the eight indicators was 32.1%. Only 58.3% (516/885) of the ceftriaxone doses prescribed were administered to completion. Complete blood count and culture and sensitivity testing rates were 38.8% (343/885) and 1.13% (10/885), respectively. Over 85.4% (756/885) of the patients improved and were discharged. Factors associated with appropriate ceftriaxone use were gender, pregnancy status, days of hospitalization, health facility level of care, health facility type, and type of prescriber.